Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 15/20 | 0.59 |
| ▸ | DDB1 | Q16531 | 11/20 | 0.59 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29617105 | 1.00 | CRBN (0.59) | CRBNDDB1IRAK4EGFRLRRK2 | |
| SCHEMBL23729950 | 1.00 | CRBN (0.59) | CRBNDDB1IRAK4EGFRLRRK2 | |
| SCHEMBL30058679 | 0.96 | CRBN (0.57) | CRBNDDB1IRAK4EGFRLRRK2 | |
| SCHEMBL23705538 | 0.96 | CRBN (0.57) | CRBNDDB1IRAK4EGFRLRRK2 | |
| SCHEMBL30893196 | 0.89 | CRBN (0.55) | CRBNDDB1IRAK4LRRK2 | |
| SCHEMBL23729684 | 0.89 | CRBN (0.62) | CRBNDDB1IRAK4EGFRLRRK2 | |
| SCHEMBL23729682 | 0.87 | CRBN (0.55) | CRBNDDB1IRAK4EGFRLRRK2 | |
| SCHEMBL26814139 | 0.87 | CRBN (0.57) | CRBNDDB1IRAK4EGFRAR | |
| SCHEMBL30893186 | 0.86 | CRBN (0.59) | CRBNDDB1IRAK4LRRK2AR | |
| SCHEMBL23705554 | 0.86 | CRBN (0.55) | CRBNDDB1IRAK4EGFRLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552775-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20250114460-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2025-04-10 | — | — | US | disclosed |
| EP-4384520-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | Uppthera, Inc. (KR) | 2024-06-19 | — | — | EP | disclosed |
| US-20240101534-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-03-28 | — | — | US | disclosed |
| US-20230150974-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-18 | — | — | US | disclosed |
| WO-2023017446-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023017442-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
| EP-4132529-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| WO-2022109396-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2022-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101534-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, BRCA1 | CRBN 163/4885DDB1 576/4885IRAK4 3130/4885 |
| US-12552775-B2 | Compounds and uses thereof | SMARCC1, SMARCC2, CHD1 | CRBN 125/4885DDB1 484/4885IRAK4 2341/4885 |
| US-20230150974-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | CRBN 179/4885DDB1 987/4885IRAK4 3032/4885 |
| US-20250114460-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | CRBN 2136/4885DDB1 132/4885IRAK4 1706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.